The Company's lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy.

Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic ...

central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia." According to the Company, "[t]he CRL indicates that the FDA completed its ...